Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease

Next Previous
Search
Trial Profile

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gantenerumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms GRADUATE-2
  • Sponsors Chugai Pharmaceutical; Roche; Roche Farma

    • Most Recent Events

    • 16 Nov 2023 Results from GRADUATE I and II trials assessing efficacy of Gantenerumab in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease, published in the New England Journal of Medicine.
    • 20 Jul 2023 Results from GRADUATE 1&2 and CLARITY, EMERGE and ENGAGE assessing Re-estimation of drug-specific amyloid removal parameters and the rate constant for pathogenic tau turnover brings the Q-ATN model presented at the Alzheimer's Association International Conference 2023
    • 20 Jul 2023 Results presented at the Alzheimer's Association International Conference 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top